Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave. / Snyman, Jumari; Hwa, Shi Hsia; Krause, Robert; Muema, Daniel; Reddy, Tarylee; Ganga, Yashica; Karim, Farina; Leslie, Alasdair; Sigal, Alex; Ndung'U, Thumbi; Archary, Moherndran; Dullabh, Kaylesh J.; Goulder, Philip; Harling, Guy; Harrichandparsad, Rohen; Herbst, Kobus; Jeena, Prakash; Khoza, Thandeka; Klein, Nigel; Kloverpris, Henrik; Madansein, Rajhmun; Marakalala, Mohlopheni; Mazibuko, Matilda; Moshabela, Mosa; Mthabela, Ntombifuthi; Naidoo, Kogie; Ndhlovu, Zaza; Nyamande, Kennedy; Padayatchi, Nesri; Patel, Vinod; Smit, Theresa; Steyn, Adrie; Wong, Emily.
In: Clinical Infectious Diseases, Vol. 75, No. 1, 2022, p. E249-E256.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and with Human Immunodeficiency Virus on Antiretroviral Therapy during the First South African Infection Wave
AU - Snyman, Jumari
AU - Hwa, Shi Hsia
AU - Krause, Robert
AU - Muema, Daniel
AU - Reddy, Tarylee
AU - Ganga, Yashica
AU - Karim, Farina
AU - Leslie, Alasdair
AU - Sigal, Alex
AU - Ndung'U, Thumbi
AU - Archary, Moherndran
AU - Dullabh, Kaylesh J.
AU - Goulder, Philip
AU - Harling, Guy
AU - Harrichandparsad, Rohen
AU - Herbst, Kobus
AU - Jeena, Prakash
AU - Khoza, Thandeka
AU - Klein, Nigel
AU - Kloverpris, Henrik
AU - Madansein, Rajhmun
AU - Marakalala, Mohlopheni
AU - Mazibuko, Matilda
AU - Moshabela, Mosa
AU - Mthabela, Ntombifuthi
AU - Naidoo, Kogie
AU - Ndhlovu, Zaza
AU - Nyamande, Kennedy
AU - Padayatchi, Nesri
AU - Patel, Vinod
AU - Smit, Theresa
AU - Steyn, Adrie
AU - Wong, Emily
N1 - Publisher Copyright: © 2021 The Author(s).
PY - 2022
Y1 - 2022
N2 - Background: There is limited understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis in African populations with a high burden of infectious disease comorbidities such as human immunodeficiency virus (HIV). The kinetics, magnitude, and duration of virus-specific antibodies and B-cell responses in people living with HIV (PLWH) in sub-Saharan Africa have not been fully characterized. Methods: We longitudinally followed SARS-CoV-2-infected individuals in Durban, KwaZulu-Natal, South Africa, and characterized SARS-CoV-2 receptor-binding domain-specific immunoglobulin (Ig) M, IgG, and IgA weekly for 1 month and at 3 months post-diagnosis. Thirty of 72 (41.7%) were PLWH, 25/30 (83%) of whom were on antiretroviral therapy (ART) with full HIV suppression. Plasma neutralization was determined using a live virus neutralization assay, and antibody-secreting cell population frequencies were determined by flow cytometry. Results: Similar seroconversion rates, time to peak antibody titer, peak magnitude, and durability of anti-SARS-CoV-2 IgM, IgG, and IgA were observed in people not living with HIV and PLWH with complete HIV suppression on ART. In addition, similar potency in a live virus neutralization assay was observed in both groups. Loss of IgA was significantly associated with age (P =. 023) and a previous diagnosis of tuberculosis (P=.018). Conclusions: Similar antibody responses and neutralization potency in people not living with HIV and PLWH on stable ART in an African setting suggest that coronavirus disease 2019 (COVID-19) natural infections may confer comparable antibody immunity in these groups. This provides hope that COVID-19 vaccines will be effective in PLWH on stable ART.
AB - Background: There is limited understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis in African populations with a high burden of infectious disease comorbidities such as human immunodeficiency virus (HIV). The kinetics, magnitude, and duration of virus-specific antibodies and B-cell responses in people living with HIV (PLWH) in sub-Saharan Africa have not been fully characterized. Methods: We longitudinally followed SARS-CoV-2-infected individuals in Durban, KwaZulu-Natal, South Africa, and characterized SARS-CoV-2 receptor-binding domain-specific immunoglobulin (Ig) M, IgG, and IgA weekly for 1 month and at 3 months post-diagnosis. Thirty of 72 (41.7%) were PLWH, 25/30 (83%) of whom were on antiretroviral therapy (ART) with full HIV suppression. Plasma neutralization was determined using a live virus neutralization assay, and antibody-secreting cell population frequencies were determined by flow cytometry. Results: Similar seroconversion rates, time to peak antibody titer, peak magnitude, and durability of anti-SARS-CoV-2 IgM, IgG, and IgA were observed in people not living with HIV and PLWH with complete HIV suppression on ART. In addition, similar potency in a live virus neutralization assay was observed in both groups. Loss of IgA was significantly associated with age (P =. 023) and a previous diagnosis of tuberculosis (P=.018). Conclusions: Similar antibody responses and neutralization potency in people not living with HIV and PLWH on stable ART in an African setting suggest that coronavirus disease 2019 (COVID-19) natural infections may confer comparable antibody immunity in these groups. This provides hope that COVID-19 vaccines will be effective in PLWH on stable ART.
KW - antibodies
KW - neutralization
KW - SARS-CoV-2
KW - South Africa
U2 - 10.1093/cid/ciab758
DO - 10.1093/cid/ciab758
M3 - Journal article
C2 - 34472583
AN - SCOPUS:85137125706
VL - 75
SP - E249-E256
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 1
ER -
ID: 333620251